Chlorzoxazone

Musculoskeletal pain is a common and frequently occurring disease in clinical practice, which includes not only soft tissue spasm caused by sports injuries and chronic strain, but also abnormal muscle tension caused by central nervous system lesions. Long-term illness can significantly reduce patients' activity ability and quality of life. Chlorzoxazone is a centrally acting skeletal muscle relaxant. It acts on the spinal cord and the subcortical center of the brain, inhibits the polysynaptic reflex related to muscle spasm, and reduces the release of pain-causing substances, so as to relieve the pain caused by spasm and improve muscle mobility. Clinically, it is mostly used for muscle pain caused by acute skeletal muscle sprain, chronic fasciitis, cervical spondylosis and lumbar disc herniation, and can also be used as an adjuvant therapeutic drug for muscle tonic spasm caused by central nervous system diseases. The applicable population covers sports people, patients with chronic strain and patients with neurogenic dystonia, etc.

In recent years, the domestic skeletal muscle relaxant market has maintained a stable expansion trend. Among them, the annual market size of therapeutic drugs that directly act on muscle spasm symptoms has exceeded 2 billion yuan, and the annual compound growth rate has maintained at around 7%. Chlorzoxazone, with the characteristics of fast onset, mild adverse reactions and good tolerance, accounts for about 12% of non-opioid analgesic muscle relaxants, and is a commonly used variety in primary medical institutions. At present, the domestic chlorzoxazone preparation market is dominated by generic drugs. More than 20 enterprises have obtained approval for the marketing of related dosage forms, the supply of API has basically been localized, the overall market competition is sufficient, and the price system has been in a people-friendly range for a long time.

The original research enterprise of chlorzoxazone is Johnson & Johnson of the United States, with the original brand name Paraflex, and its core compound patent expired in 1987. The original research dosage forms are mainly 250mg and 500mg oral tablets, and the original research products have not been marketed in China. The domestic marketed chlorzoxazone preparations include tablets, capsules, compound preparations, etc., among which tablets of 200mg and 250mg specifications have been included in the National Essential Medicine List. Up to now, there are 8 domestic chlorzoxazone API registration information on the CDE API registration platform, 6 of which are in status A and can be used for associated review, and another 1 imported API registration information is in status I. (Data as of July 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of chlorzoxazone impurity reference standards. Most products are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. At the same time, all reference standards comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, which can fully meet the full-process needs of API manufacturers in process research, quality research, registration and declaration, etc.